Rm-PgP
Spinal Cord Injury / Traumatic Brain Injury
Pre-clinicalActive
Key Facts
Indication
Spinal Cord Injury / Traumatic Brain Injury
Phase
Pre-clinical
Status
Active
Company
About NeuroHope Therapeutics
NeuroHope Therapeutics is a private, preclinical-stage biopharmaceutical company founded in 2020 and based in Cambridge, Massachusetts, with a stated operational base in South Carolina. The company is developing a proprietary polymeric nanoparticle platform (PgP) designed for localized, sustained drug delivery to the central nervous system, aiming to overcome significant treatment challenges in neurotrauma. Its lead program, Rm-PgP, targets spinal cord injury and has demonstrated promising preclinical efficacy in rat models, showing improved motor recovery and reduced neuroinflammation. The company is pre-revenue and focused on advancing its nanotherapeutic platform toward clinical development.
View full company profile